RATIONALE: Glutamatergic dysfunction at N-methyl-D: -aspartate (NMDA) receptors has been proposed as a neurochemical model for schizophrenia. A key feature of this disorder is impairments in cognitive function. OBJECTIVE: The present study sought to investigate the effects of ketamine, an NMDA antagonist, on the performance and neural correlates of verbal fluency, a task that engages executive function. METHODS:Ten healthy dextral male volunteers received intravenous placebo normal saline or ketamine (bolus of 0.23 mg/kg and infusion of 0.65 mg/kg), administered in a double-blind, randomized order, during two functional magnetic resonance imaging sessions. During scanning, subjects performed a verbal fluency task. Two levels of cognitive load were examined in the task, and overt responses were acquired in order to measure subject performance on-line. RESULTS:Ketamine induced symptoms in the healthy individuals comparable to an acute psychotic state. Although ketamine did not significantly impair task performance relative to placebo, an interaction of task demand with ketamine was observed in the anterior cingulate, prefrontal, and striatal regions. CONCLUSIONS: The behavioural and functional effects of ketamine during verbal fluency in healthy individuals were comparable to those evident in patients with schizophrenia. The findings support a role for glutamatergic dysfunction in the pathophysiology of schizophrenia.
RCT Entities:
RATIONALE: Glutamatergic dysfunction at N-methyl-D: -aspartate (NMDA) receptors has been proposed as a neurochemical model for schizophrenia. A key feature of this disorder is impairments in cognitive function. OBJECTIVE: The present study sought to investigate the effects of ketamine, an NMDA antagonist, on the performance and neural correlates of verbal fluency, a task that engages executive function. METHODS: Ten healthy dextral male volunteers received intravenous placebo normal saline or ketamine (bolus of 0.23 mg/kg and infusion of 0.65 mg/kg), administered in a double-blind, randomized order, during two functional magnetic resonance imaging sessions. During scanning, subjects performed a verbal fluency task. Two levels of cognitive load were examined in the task, and overt responses were acquired in order to measure subject performance on-line. RESULTS:Ketamine induced symptoms in the healthy individuals comparable to an acute psychotic state. Although ketamine did not significantly impair task performance relative to placebo, an interaction of task demand with ketamine was observed in the anterior cingulate, prefrontal, and striatal regions. CONCLUSIONS: The behavioural and functional effects of ketamine during verbal fluency in healthy individuals were comparable to those evident in patients with schizophrenia. The findings support a role for glutamatergic dysfunction in the pathophysiology of schizophrenia.
Authors: E T Bullmore; J Suckling; S Overmeyer; S Rabe-Hesketh; E Taylor; M J Brammer Journal: IEEE Trans Med Imaging Date: 1999-01 Impact factor: 10.048
Authors: V A Curtis; E T Bullmore; R G Morris; M J Brammer; S C Williams; A Simmons; T Sharma; R M Murray; P K McGuire Journal: Schizophr Res Date: 1999-05-04 Impact factor: 4.939
Authors: C D Frith; K J Friston; S Herold; D Silbersweig; P Fletcher; C Cahill; R J Dolan; R S Frackowiak; P F Liddle Journal: Br J Psychiatry Date: 1995-09 Impact factor: 9.319
Authors: Jason P Caplan; Lucy A Epstein; Davin K Quinn; Jonathan R Stevens; Theodore A Stern Journal: Neuropsychol Rev Date: 2007-08-16 Impact factor: 7.444
Authors: P Fusar-Poli; M R Broome; P Matthiasson; J B Woolley; A Mechelli; L C Johns; P Tabraham; E Bramon; L Valmaggia; S C Williams; P McGuire Journal: Schizophr Bull Date: 2009-08-07 Impact factor: 9.306
Authors: Dawn F Ionescu; Julia M Felicione; Aishwarya Gosai; Cristina Cusin; Philip Shin; Benjamin G Shapero; Thilo Deckersbach Journal: Harv Rev Psychiatry Date: 2018 Nov/Dec Impact factor: 3.732
Authors: Naomi R Driesen; Gregory McCarthy; Zubin Bhagwagar; Michael H Bloch; Vincent D Calhoun; Deepak C D'Souza; Ralitza Gueorguieva; George He; Hoi-Chung Leung; Ramachandran Ramani; Alan Anticevic; Raymond F Suckow; Peter T Morgan; John H Krystal Journal: Neuropsychopharmacology Date: 2013-07-16 Impact factor: 7.853
Authors: M Steffens; B Becker; C Neumann; A M Kasparbauer; I Meyhöfer; B Weber; M A Mehta; R Hurlemann; U Ettinger Journal: Hum Brain Mapp Date: 2016-11 Impact factor: 5.038
Authors: Albert R Powers; Mark G Gancsos; Emily S Finn; Peter T Morgan; Philip R Corlett Journal: Psychopathology Date: 2015-09-12 Impact factor: 1.944